

Title (en)

DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION

Title (de)

DARREICHUNGSFORMEN UND VERFAHREN FÜR ENANTIOMER ANGEREICHERTES ODER REINES BUPROPION

Title (fr)

FORMES POSOLOGIQUES ET PROCÉDÉS POUR OBTENIR DU BUPROPION ÉNANTIOMÉRIQUEMENT ENRICHI OU PUR

Publication

EP 3755312 A1 20201230 (EN)

Application

EP 19756920 A 20190225

Priority

- US 201862634718 P 20180223
- US 201962794469 P 20190118
- US 201962809480 P 20190222
- US 2019019445 W 20190225

Abstract (en)

[origin: WO2019165379A1] Described herein are dosage forms of enantiomerically enriched (S)-bupropion or enantiomerically enriched (R)-bupropion. The (S)-bupropion or the (R)-bupropion may be deuterium enriched, or may have natural isotopic abundance. These dosage forms may be administered, either fed or fasted, to treat a condition recited herein, to achieve a certain pharmacokinetic parameter of a bupropion or a metabolite of a bupropion, and/or to enhance dextromethorphan plasma levels.

IPC 8 full level

A61K 31/137 (2006.01); **A61K 31/485** (2006.01); **A61P 25/00** (2006.01); **A61P 25/18** (2006.01); **A61P 25/24** (2006.01); **A61P 25/28** (2006.01); **A61P 25/30** (2006.01)

CPC (source: EP IL KR)

A61K 9/0053 (2013.01 - KR); **A61K 31/137** (2013.01 - EP IL KR); **A61K 31/485** (2013.01 - EP IL); **A61K 45/06** (2013.01 - EP IL); **A61P 25/00** (2018.01 - EP IL KR); **A61P 25/18** (2018.01 - EP IL KR); **A61P 25/24** (2018.01 - EP IL KR); **A61P 25/28** (2018.01 - EP IL KR); **A61P 25/30** (2018.01 - EP IL KR); **A61K 2300/00** (2013.01 - IL)

C-Set (source: EP)

1. **A61K 31/485 + A61K 2300/00**
2. **A61K 31/137 + A61K 2300/00**

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2019165379 A1 20190829; AU 2019223187 A1 20200917; AU 2019223187 B2 20220728; AU 2022204521 A1 20220721; AU 2022204521 B2 20240905; AU 2024205858 A1 20240905; BR 112020017179 A2 20201222; CA 3092076 A1 20190829; CL 2020002166 A1 20201023; CN 112087999 A 20201215; CR 20200415 A 20210203; EC SP20060179 A 20201231; EP 3755312 A1 20201230; EP 3755312 A4 20220316; IL 276871 A 20201029; IL 276871 B1 20240701; IL 313368 A 20240801; JP 2021513998 A 20210603; JP 2022153638 A 20221012; JP 2024075655 A 20240604; KR 20210003091 A 20210111; KR 20230075531 A 20230531; KR 20240091043 A 20240621; MA 51914 A 20201230; MX 2020008704 A 20201207; MX 2023009281 A 20230817; NI 202000056 A 20210111; NZ 767378 A 20240322; PE 20211752 A1 20210906; SG 11202008056S A 20200929

DOCDB simple family (application)

US 2019019445 W 20190225; AU 2019223187 A 20190225; AU 2022204521 A 20220627; AU 2024205858 A 20240817; BR 112020017179 A 20190225; CA 3092076 A 20190225; CL 2020002166 A 20200821; CN 201980026874 A 20190225; CR 20200415 A 20190225; EC DI202060179 A 20200923; EP 19756920 A 20190225; IL 27687120 A 20200823; IL 31336824 A 20240605; JP 2020544420 A 20190225; JP 2022124557 A 20220804; JP 2024041381 A 20240315; KR 20207027256 A 20190225; KR 20237017449 A 20190225; KR 20247017593 A 20190225; MA 51914 A 20190225; MX 2020008704 A 20190225; MX 2023009281 A 20200820; NI 202000056 A 20200821; NZ 76737819 A 20190225; PE 2020001272 A 20190225; SG 11202008056S A 20190225